Allovir Q3 2022 Earnings Report
Key Takeaways
AlloVir reported a net loss of $42.1 million, or $0.50 per share, for the third quarter ended September 30, 2022. The company's research and development expenses were $30.0 million, and general and administrative expenses were $12.9 million. As of September 30, 2022, AlloVir had cash, cash equivalents, and marketable securities of $264.1 million.
Posoleucel continues to advance in three ongoing multi-national Phase 3 registrational trials.
Final data presentation from Posoleucel Phase 2 multi-virus prevention study by year-end.
Final topline data from Posoleucel Phase 2 study for treatment of BK Viremia in kidney transplant patients on track to be released in Q1 2023.
AlloVir plans to host an investor webcast on December 14 to discuss the unmet medical need for and clinical value of a multi-virus prevention approach in the management of allo-HCT patients.